Paul Mitchell, AAO 2018 – Age-related Macular Degeneration and the ARIES Study
The ARIES trial compares an early versus a late start for a treat-and-extend (T&E) regimen, an increasingly popular approach to treatment worldwide, for wet or neovascular age-related macular degeneration (AMD). Professor Paul Mitchell gives an overview of the study, and discusses wet AMD and the differences to dry AMD, the specifics and benefits of the T&E regimen and the importance of dosing frequency in real-world cases.
Questions:
1. Could you please summarise the study design, rationale and aims of the ongoing ARIES clinical trial? What is unique with the ARIES study? (0:11)
2. What is wet age-related macular degeneration (also known as neovascular AMD), and how does it differ in pathogenesis and manifestation from dry AMD? (1:46)
3. What is aflibercept, and how does it differ from other anti-VEGF drugs? (2:42)
4. How does the treat-and-extend (T&E) regimen differ from a monthly treatment regimen? Are there any benefits of T&E compared with monthly treatment? (3:20)
5. How important is the dosing frequency for real-world AMD treatment from the point of view of both patients and clinicians? (4:11)
Speaker disclosures: Paul Mitchell is a speaker for Bayer.
Filmed at the American Academy of Ophthalmology (AAO) 2018 Annual Meeting, Chicago, IL, US, 27–30 October 2018.
